Last updated: October 6, 2026
Sulfamethoxazole and trimethoprim, commonly called trimethoprim-sulfamethoxazole or TMP-SMX, is a mature generic antibacterial with broad clinical use and limited patent protection. The market is driven by prescription volume, hospital and outpatient demand, manufacturing reliability, and reimbursement pressure rather than branded pricing or exclusivity. Bactrim and Septra patents expired many years ago, FDA generic competition is extensive, and no biosimilar pathway applies because the product is a small-molecule drug.
Financial performance is therefore concentrated in manufacturing scale, contract supply, portfolio breadth, and shortage management. Product-level revenue is generally not disclosed by generic manufacturers, while global market estimates vary by scope and methodology.
What is sulfamethoxazole and trimethoprim used for?
Sulfamethoxazole and trimethoprim combines a sulfonamide antibiotic with a dihydrofolate-reductase inhibitor. The combination produces sequential inhibition of bacterial folate synthesis.
The FDA-approved indications include:
- Urinary tract infections
- Acute otitis media in children
- Acute exacerbations of chronic bronchitis
- Shigellosis
- Pneumocystis jirovecii pneumonia treatment and prophylaxis
- Traveler’s diarrhea caused by susceptible organisms
The most common oral strengths are:
| Dosage form |
Sulfamethoxazole |
Trimethoprim |
Common commercial description |
| Single-strength tablet |
400 mg |
80 mg |
TMP-SMX 400/80 |
| Double-strength tablet |
800 mg |
160 mg |
TMP-SMX 800/160, or DS |
| Oral suspension, 5 mL |
200 mg |
40 mg |
Pediatric liquid |
| Injection |
400 mg per 5 mL |
80 mg per 5 mL |
Concentrated IV product |
FDA labeling identifies the product as an antibacterial combination for susceptible infections and includes warnings relating to hypersensitivity, severe skin reactions, hematologic toxicity, renal impairment, hyperkalemia, and interactions with drugs including warfarin and certain renin-angiotensin system inhibitors (FDA, 2023).
How large is the sulfamethoxazole and trimethoprim market?
The market is a high-volume, low-price generic segment rather than a premium pharmaceutical franchise.
Public market reports typically group TMP-SMX into broader categories such as antibacterial drugs, sulfonamides, urinary anti-infectives, or generic antibiotics. Reported market values are therefore not directly comparable. The major commercial indicators are:
| Market factor |
Current commercial effect |
| Product age |
Removes branded pricing power and exclusivity |
| Generic competition |
Compresses average selling prices |
| Clinical familiarity |
Supports recurring demand |
| Broad indications |
Diversifies use across outpatient, inpatient, and prophylaxis settings |
| Low unit cost |
Limits absolute revenue per prescription |
| Manufacturing concentration |
Creates periodic supply and shortage risk |
| Pediatric and injectable forms |
Preserve differentiated contract and institutional demand |
The product remains commercially relevant because clinicians use it for several distinct indications, including community urinary infections, methicillin-resistant Staphylococcus aureus treatment in selected cases, and Pneumocystis prophylaxis. Its role is constrained by antimicrobial resistance, allergy, renal dosing requirements, and safety concerns.
No major originator company reports a current, separately identifiable global revenue stream for TMP-SMX. Generic manufacturers generally include the product within broader revenue categories. As a result, product-level financial analysis must rely on prescription volume, procurement data, wholesaler activity, and public-sector purchasing rather than audited product sales.
When did sulfamethoxazole and trimethoprim lose exclusivity?
Sulfamethoxazole and trimethoprim lost meaningful commercial exclusivity decades ago. The original branded products were introduced in the 1970s, and the core composition-of-matter and product protections are no longer commercially relevant.
Roche commercialized Bactrim, while Burroughs Wellcome commercialized Septra in the United States. The FDA approved Bactrim in the 1970s, before the modern Hatch-Waxman generic framework took effect. Generic approvals followed over subsequent decades.
Key exclusivity timeline
| Milestone |
Approximate timing |
Commercial significance |
| Original U.S. branded approvals |
1970s |
Established Bactrim and Septra franchises |
| Hatch-Waxman Act |
1984 |
Created the modern ANDA pathway for later generic applicants |
| Early generic entry |
1980s-1990s |
Began sustained price competition |
| Core brand exclusivity |
Expired decades ago |
Removed meaningful branded protection |
| Current market |
Mature generic |
Competition is based on cost, supply, quality, and distribution |
The precise patent histories for Bactrim and Septra include legacy patents and regulatory records that predate the current commercial market. Those patents do not create an effective barrier to generic entry today.
What is the Orange Book status of sulfamethoxazole and trimethoprim?
The Orange Book does not provide a meaningful current patent barrier for standard oral TMP-SMX products. The relevant FDA listings are primarily generic approvals and legacy reference-product information rather than active exclusivity that prevents competition.
For a generic applicant, the commercial pathway is typically an abbreviated new drug application referencing the applicable reference-listed drug. Because the product has been generic for many years, the principal regulatory issues are bioequivalence, product quality, labeling, manufacturing controls, and supply continuity.
Orange Book and regulatory implications
- No current brand exclusivity protects the standard oral combination.
- No biologic license application is involved.
- No biosimilar pathway applies.
- ANDA approvals are the principal route for generic competition.
- Product-specific patent disputes are not a major current market determinant.
- Formulation-specific regulatory requirements may still affect approval timing.
FDA Orange Book records and Drugs@FDA identify the reference-product framework and approved applications, while DailyMed provides current labeling for marketed products (FDA, n.d.-a; FDA, n.d.-b).
What patents protect sulfamethoxazole and trimethoprim?
No commercially significant active patent estate protects the basic TMP-SMX combination, its standard strengths, or its conventional oral dosage forms.
Composition patents
The active ingredients are old small molecules. The original combination and core antibacterial use are outside the practical life of pharmaceutical composition patents.
Formulation patents
Standard tablets, double-strength tablets, oral suspensions, and conventional injectable formulations have long been subject to generic competition. A manufacturer could obtain protection for a novel delivery system, excipient system, packaging configuration, or manufacturing process, but those rights would not block ordinary TMP-SMX products unless they covered a commercially necessary feature.
Method-of-use patents
The established uses, including urinary tract infection treatment and Pneumocystis prophylaxis, are longstanding clinical applications. They are not protected by commercially material exclusivity in the current market.
Manufacturing and process protection
Manufacturing know-how can still have value. Relevant areas include:
- API sourcing and qualification
- Control of impurity profiles
- Particle-size management
- Suspension stability
- Sterility assurance for injectable products
- Packaging and moisture protection
- Yield optimization and batch-scale economics
These protections are generally trade secrets or process controls rather than blocking patents. Their value is operational. They can affect cost, quality, and supply continuity without preventing another company from marketing a competing product.
Which companies compete in the TMP-SMX market?
Competition is fragmented across generic pharmaceutical companies, contract manufacturers, and regional suppliers. Market participation varies by dosage form and jurisdiction.
Companies that have marketed or supplied TMP-SMX products in the United States and other regulated markets include:
- Teva Pharmaceutical Industries
- Hikma Pharmaceuticals
- Amneal Pharmaceuticals
- Rising Pharmaceuticals
- Solco Healthcare
- Sandoz and other Novartis-related generic operations
- Perrigo and regional pediatric-suspension suppliers
- Hospital and institutional injectable suppliers
The competitive structure differs by product:
| Product segment |
Competitive profile |
| 800/160 mg tablets |
Broad generic competition and severe price pressure |
| 400/80 mg tablets |
Mature commodity market |
| Oral suspension |
Fewer qualified suppliers because of stability, taste, and pediatric-use requirements |
| Injection |
More dependent on sterile manufacturing capacity and hospital contracts |
| Public-sector supply |
Procurement and tender pricing dominate |
| Retail prescriptions |
Pharmacy benefit reimbursement and wholesaler discounts dominate |
Brand recognition for Bactrim remains clinically useful, but it does not translate into the pricing power associated with protected branded medicines.
How strong is the patent estate for sulfamethoxazole and trimethoprim?
The patent estate is weak from a blocking perspective and moderate only in relation to manufacturing execution.
| Patent or exclusivity category |
Strength |
| Core composition |
None of practical current value |
| Standard oral tablets |
Weak or absent |
| Oral suspension |
Limited product-specific protection; technical barriers may remain |
| Injectable formulation |
Limited patent barrier; sterile manufacturing is more important |
| Method of use |
No meaningful current exclusivity |
| API manufacturing |
Potential process know-how, but usually nonblocking |
| Packaging and device |
Limited relevance for conventional products |
| Regulatory exclusivity |
None of material current significance |
The competitive moat is therefore operational. A supplier with multiple approved sites, reliable API access, validated analytical methods, and strong regulatory compliance can outperform a nominally interchangeable competitor.
What generic entry risks exist for TMP-SMX?
Generic-entry risk is already realized rather than prospective. The market has experienced extensive entry, and additional entrants would usually reduce prices rather than create a new competitive shock.
The principal risks to incumbent suppliers are:
- Price erosion from additional ANDA holders.
- Loss of preferred wholesaler or group-purchasing contracts.
- FDA manufacturing observations or warning letters.
- API supply interruptions.
- Product recalls caused by dissolution, contamination, stability, or labeling issues.
- Reduced prescribing caused by resistance or safety concerns.
- Hospital substitution toward alternative antibiotics.
- Reimbursement changes affecting low-cost generic dispensing.
For buyers, the main risk is the opposite: too few suppliers in selected presentations can increase shortage exposure.
Are there Paragraph IV challenges or patent litigation?
Paragraph IV litigation is not a central current issue for standard TMP-SMX products. Paragraph IV certifications matter most when an ANDA applicant challenges an unexpired listed patent. The core TMP-SMX market is too mature for ordinary tablet products to generate the litigation profile seen with newer branded drugs.
The more relevant legal issues are:
- Product liability claims
- Manufacturing and quality disputes
- Contract and supply agreements
- Antitrust issues involving generic supply
- False claims or reimbursement matters
- Labeling and pharmacovigilance disputes
- Shortage-related procurement and allocation conflicts
There is no known current patent dispute that materially prevents generic access to conventional TMP-SMX tablets, suspension, or injection. The lack of active blocking litigation reflects the age of the product and the absence of commercially significant Orange Book patents.
What is the FDA regulatory status of TMP-SMX?
TMP-SMX is an FDA-approved prescription antibacterial available in oral and injectable forms. The product is not a biologic and does not require a biosimilar review.
FDA regulatory priorities include:
- Demonstration of bioequivalence for tablets and suspension
- Consistency of trimethoprim-to-sulfamethoxazole ratio
- Dissolution performance
- Suspension uniformity and stability
- Sterility and particulate control for injection
- Accurate pediatric dosing information
- Adverse-event monitoring
- Compliance with current good manufacturing practices
The drug’s age does not eliminate regulatory risk. Mature generics can face supply disruption when a manufacturer exits, an API source fails qualification, or a sterile facility encounters compliance problems.
How does TMP-SMX compare with competing antibiotics?
TMP-SMX competes with several inexpensive antibiotics, but the competitive set changes by indication.
| Use case |
TMP-SMX competitors |
TMP-SMX advantage |
Main limitation |
| Uncomplicated UTI |
Nitrofurantoin, fosfomycin, fluoroquinolones |
Low cost and oral convenience |
Resistance and allergy |
| Skin and soft-tissue infection |
Doxycycline, clindamycin |
MRSA activity in selected settings |
Limited streptococcal coverage |
| Pneumocystis prophylaxis |
Atovaquone, dapsone, aerosolized pentamidine |
Strong efficacy and low cost |
Cytopenias, renal and allergic toxicity |
| Shigellosis |
Azithromycin, ceftriaxone, fluoroquinolones |
Familiar oral option |
Resistance |
| Pediatric infection |
Amoxicillin, cephalosporins, macrolides |
Broad historical use |
Sulfonamide allergy and age-specific restrictions |
The product retains demand where susceptibility is favorable and cost matters. It loses share when resistance data, patient comorbidities, or adverse-effect risk favor another antibiotic.
What is the financial trajectory for TMP-SMX?
The financial trajectory is stable to declining on a unit-price basis, with intermittent volume resilience.
Revenue drivers
- High prescription volume
- Persistent use in outpatient infections
- Long-term Pneumocystis prophylaxis
- Low manufacturing cost at scale
- Institutional demand for injectable products
- Public-sector and international procurement
Revenue constraints
- Generic price compression
- Limited differentiation
- No exclusivity
- Low reimbursement ceilings
- Resistance-driven substitution
- Safety-related prescribing restrictions
- Limited ability to raise prices without attracting competitors or regulatory scrutiny
For large generic companies, TMP-SMX is more likely to be a portfolio-support product than a material standalone growth asset. Its value lies in recurring demand, manufacturing utilization, and inclusion in hospital or retail contracts. For smaller suppliers, profitability depends on avoiding quality failures and maintaining adequate supply during competitor exits.
What licensing deals and commercial partnerships affect the market?
No major recent licensing transaction has transformed the conventional TMP-SMX market. Commercial arrangements generally involve:
- Contract manufacturing
- Authorized distribution
- Private-label supply
- Hospital purchasing agreements
- Government tenders
- API sourcing
- Regional marketing rights
These arrangements can change market share without changing patent ownership. A supplier with an approved product but weak distribution may have less commercial value than a contract manufacturer with reliable institutional access.
What geographic markets matter most?
The United States is a large, highly genericized market with strong pharmacy benefit pressure. Europe has similarly low prices but different national procurement systems and regulatory requirements. Emerging markets can generate substantial unit demand, especially for oral tablets and pediatric suspension, but prices are lower and quality oversight varies by jurisdiction.
Geographic value is influenced by:
- National essential-medicine policies
- Local antibiotic resistance
- Public procurement
- Registration requirements
- API import dependence
- Currency movements
- Local manufacturing incentives
- Hospital tender structures
The product’s commercial opportunity is larger in units than in revenue. International growth is therefore unlikely to produce branded-drug economics.
Key Takeaways
- TMP-SMX is a mature, heavily genericized antibacterial combination.
- Bactrim and Septra no longer have commercially meaningful exclusivity.
- Standard tablets, suspension, and injection face no material current patent barrier.
- Paragraph IV litigation is not a major market driver.
- Biosimilar risk is irrelevant because TMP-SMX is a small molecule.
- Revenue is driven by volume, tenders, manufacturing efficiency, and supply reliability.
- Oral tablets are highly price-competitive; suspension and injectable products have more operational barriers.
- The product has durable clinical demand but limited pricing power.
- Financial performance is best analyzed at the portfolio or contract level because manufacturers rarely disclose TMP-SMX revenue separately.
- The main investment risk is supply and quality execution, not patent expiry.
FAQs About Sulfamethoxazole and Trimethoprim
Is Bactrim still patent protected?
No commercially significant patent protection remains for conventional Bactrim-equivalent products. Generic versions have been marketed for decades.
Is sulfamethoxazole and trimethoprim a biologic?
No. It is a conventional small-molecule combination antibiotic and is regulated through the standard drug approval and generic pathways.
Can a generic company launch TMP-SMX without a Paragraph IV challenge?
Yes. Because the relevant product is mature and lacks a material blocking patent estate, a generic applicant generally does not face the same Paragraph IV exposure associated with newer branded medicines.
Why can TMP-SMX face shortages despite having no patent barrier?
Shortages can result from API concentration, low generic margins, manufacturing failures, sterile-facility disruptions, recalls, and supplier exits. Patent freedom does not guarantee manufacturing capacity.
Which TMP-SMX dosage form has the strongest commercial position?
The 800/160 mg double-strength tablet has the strongest volume position in many markets. Oral suspension and injectable products can have better supplier economics because they involve more demanding formulation or manufacturing requirements.
References
-
U.S. Food and Drug Administration. (2023). BACTRIM DS (sulfamethoxazole and trimethoprim) prescribing information. FDA.
-
U.S. Food and Drug Administration. (n.d.-a). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA. https://www.accessdata.fda.gov/scripts/cder/ob/
-
U.S. Food and Drug Administration. (n.d.-b). Drugs@FDA: FDA-approved drugs. FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
-
U.S. National Library of Medicine. (n.d.). DailyMed: Sulfamethoxazole and trimethoprim drug labeling. National Library of Medicine. https://dailymed.nlm.nih.gov/
-
U.S. Food and Drug Administration. (n.d.-c). Drug shortages database. FDA. https://www.accessdata.fda.gov/scripts/drugshortages/
